A comprehensive view of Ridgeback Biotherapeutics LP. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Emergent Biosolutions to manufacture, distribute Ridgeback Biotherapeutics’ Ebola injectable antibody therapy Ebanga ansuvimab-zykl in US, Canada; Ridgeback to remain global access partner for Ebanga in endemic countries

HHS reports sales of Pfizer’s COVID-19 oral antiviral Paxlovid outpaced drugs from other firms; 162,000 Paxlovid courses used in US in past week compared to 20,000 courses of Merck and Ridgeback’s Lagevrio, 16,000 courses of AstraZeneca’s Evusheld

Merck and Ridgeback Biotherapeutics highlight milestone manufacture of 10 million courses of molnupiravir, an investigational oral COVID-19 medicine; companies have provided 3.1 million courses to the US government

Merck and Ridgeback Biotherapeutics announces preclinical data showing molnupiravir active against the Omicron variant of the coronavirus

Merck and Ridgeback Biotherapeutics enter long-term agreement with UNICEF for supply of up to 3 million treatment courses of molnupiravir, an investigational oral COVID-19 medicine

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count